On May 21, 2024, MindRank, a clinical-stage AI-driven innovative drug discovery company, and Zhejiang Hisun Pharmaceutical Co., Ltd. (referred to as "HISUN," 600267.SH) jointly signed the "Strategic Cooperation Agreement."Both parties will adhere to the principles of friendly cooperation and mutual benefit, leveraging their respective existing platform technologies, R&D facilities, and production resources, among other inherent advantages, to engage in long-term, in-depth collaboration in fields such as AI-assisted small molecule novel drug development.
HISUN President Xiao Weihong, Vice General Manager of the R&D Center and Dean of the Innovative Drug Research Institute Dr. Zhou Houjiang, MindRank founder and CEO Niu Zhangming, Co-founder and China President Dr. Zhang Long, and others jointly attended the signing ceremony.
As one of the first innovative enterprises in China, HISUN possesses high-level, multi-dimensional R&D platforms. It has established research centers in multiple locations such as Taizhou headquarters, Shanghai, Hangzhou, and the United States. The company owns top-tier R&D platforms including a national-level enterprise technology center, Zhejiang's first postdoctoral research workstation with independent recruitment qualifications, and a key laboratory at the provincial level in Zhejiang, demonstrating full-chain drug R&D capabilities. Through this collaboration, "MindRank" will fully leverage the technical advantages of its world-leading one-stop AI-driven new drug R&D platform.Collaborate with HISUN to promote the R&D of small molecule innovative drugs in multiple disease fields.
HISUN President Xiao WeihongHISUN, a traditional pharmaceutical company with nearly 70 years of history, and MindRank, an AI-driven innovative drug discovery company led by young scientists and entrepreneurs, both share pragmatic working styles and compatible spirits, which will undoubtedly spark new ideas and integration. Through this strategic cooperation agreement, leveraging MindRank’s expertise in artificial intelligence and computer-aided drug discovery, both parties will jointly promote the construction of a new generation AI + drug discovery platform, accelerate differentiated innovative drug development, achieve more breakthrough innovations in a shorter time, and provide patients with more effective clinical treatment options.
"MindRank" Founder Zhangming Niu, Co-founder Dr. Long ZhangMindRank continuously pushes the boundaries of AI-driven drug discovery through relentless innovation, making more diseases treatable and restoring health to more lives. This aligns perfectly with HISUN's philosophy of "Devoted to Good Medicine, Fulfilling the Dream of Health." We hope to leverage HISUN’s integrated platform for innovative drug research and development, along with its robust end-to-end industrial chain capabilities in R&D, production, and sales, to jointly promote the integration of artificial intelligence and new drug discovery, and develop products with greater differentiation and high clinical value.
About HISUN
Zhejiang Hisun Pharmaceutical Co., Ltd. was founded in 1956 and went public with an A-share listing in 2000. It is a state-controlled listed company. After more than 60 years of development, HISUN has become a comprehensive pharmaceutical enterprise group integrating the entire value chain of research, production, and sales, with vertical integration of active pharmaceutical ingredients and formulations. The company focuses on the development of multiple industries including chemical drugs, biologics, veterinary drugs, traditional Chinese medicine, and commercial distribution. It is accelerating its expansion into emerging markets such as the broader health industry and aesthetic health. HISUN has been repeatedly included in the top 500 lists of China’s manufacturing enterprises and the top 100 pharmaceutical industrial enterprises in China. It has successively received honors such as National Technological Innovation Demonstration Enterprise, National May Day Labor Medal, and Zhejiang Provincial Government Quality Award.